A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- NON RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 50
- Population
- ALL · 18 Years
- Duration
- 2022-08-31 to 2025-09-30
- Intervention
- D-4517.2
- Comparator
- Not reported
- Outcomes measured
- Stage 1 Safety Evaluation — 12 weeks; Stage 1A Safety Evaluation — 40 Weeks; Stage 1: Number of participants with a reduction in sub-retinal fluid after a single intravitreal (IVT) dose of afliber…; Stage 1: Number of participants with duration of effect of D-4517.2 as assessed by changes in subretinal fluid over tim…; Stage 1: Number of participants with Ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs) obser…; Stage 1: Number of participants with change in best corrected visual acuity (BCVA) in study eye after each treatment (a…; Stage 1A: Effect of different D-4517.2 dose regimens to maintain BCVA and CST following a single IVT aflibercept dose —…; Stage 1A: Pharmacokinetics (Cmax) of D-4517.2 Repeat Dosing — 24 Weeks; Stage 1A: Pharmacokinetics (AUC) of D-4517.2 Repeat Dosing — 24 Weeks; Stage 1A: Pharmacokinetics (Tmax) of D-4517.2 Repeat Dosing — 24 Weeks; Stage 1A: Pharmacokinetics (CL/F) of D-4517.2 Repeat Dosing — 24 Weeks; Stage 1A: Rescue Treatment — 12 weeks of Aflibercept and 40 weeks of D-4517.2
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.